Journal of Traditional Medical Complementary Therapies

.: REVIEW
The Potential Role of Plants in the Treatment of Parkinson's Disease: Traditional Review
Bitkilerin Parkinson Hastalığının Tedavisindeki Potansiyel Rolü: Geleneksel Derleme
Serap CANLIa , Mehlika BENLİb
aDepartment of Elderly Care, Ankara University Haymana Vocational School, Ankara, Türkiye
bDepartment of Biology, Ankara University Faculty of Science, Ankara, Türkiye
J Tradit Complem Med. 2023;6(2):184-93
doi: 10.5336/jtracom.2023-95519
Article Language: EN
Full Text
ABSTRACT
 Parkinson is a slowly progressive brain disease of a neurodegenerative nature. It is manifested by a lack of dopamine in the brain. This neurological disease is usually seen over the age of 60. It has major symptoms such as resting tremor, bradykinesia, rigidity and posterior reflex disorder. In the studies conducted, the cause of neural degeneration is not fully explained, but it is agreed that hereditary predisposition, environmental toxins and aging play an important role and it is a multifactorial disease. Parkinson's treatment is lifelong and the dopamine hormone supplements used in treatment are aimed at reducing symptoms. A lots of herbal products contain active components which are known to possess antioxidant action. Hence, the potential role of herbal products in treating Parkinson's disease (PD) cannot be undermined. In our article, some plants used to reduce the symptoms of PD and their mechanisms of action are discussed. Among these plants are Acanthopanax senticosus, Anemopaegma mirandum, Bacopa monniera, Scutellaria baicalensis Georgi (Labiatae), Bushen Huoxue Granuls, Carthamus tinctorius L., Cassiae semen, Centella asiatica, Chrysanthemum morifolium Ramat, Chunghyuldan, Curcuma longa, Erythrina velutina Willd, Gastrodia elata Blume, Ginkgo biloba, Hypericum perforatum, Juglandis semen (Walnut), Lycium barbarum L. (Gojiberry fruit), Mucuna pruriens (Velvet bean), Paeoniae Alba Radix (White Peony Root), Peganum harmala L., Plumbago scandens, Pueraria lobata, Resveratrol, Thuja orientalis and Vicia faba (Fava Bean). With further studies, it is possible to prepare new drugs from these naturally sourced herbs.

Keywords: Aged; Parkinson's disease; medicinal plants; traditional medicine
ÖZET
 Parkinson, nörodejeneratif nitelikte yavaş ilerleyen bir beyin hastalığıdır. Beyinde dopamin eksikliği ile kendini gösterir. Bu nörolojik hastalık genellikle 60 yaş üzerinde görülür. İstirahat tremoru, bradikinezi, rijidite ve posterior refleks bozukluğu gibi majör semptomları vardır. Yapılan çalışmalarda, nöral dejenerasyonun nedeni tam olarak açıklanamamakla birlikte kalıtsal yatkınlık, çevresel toksinler ve yaşlanmanın önemli rol oynadığı ve multifaktöriyel bir hastalık olduğu kabul edilmektedir. Parkinson tedavisi ömür boyu sürer ve tedavide kullanılan dopamin hormon takviyeleri ile semptomların azaltılması amaçlanır. Birçok bitki antioksidan etkiye sahip olduğu bilinen aktif bileşenler içermektedir. Bu nedenle bitkilerin Parkinson hastalığının tedavisindeki potansiyel rolü göz ardı edilmemelidir. Yazımızda, Parkinson hastalığının semptomlarını azaltmak için kullanılan bazı bitkiler ve etki mekanizmaları ele alınmıştır. Bu bitkiler arasında Acanthopanax senticosus, Anemopaegma mirandum, Bacopa monniera, Scutellaria baicalensis Georgi (Labiatae), Bushen Huoxue Granuls, Carthamus tinctorius L., Cassiae semen, Centella asiatica, Chrysanthemum morifolium Ramat, Chunghyuldan, Curcuma longa, Erythrina velutina Willd, Gastrodia elata Blume, Ginkgo biloba, Hypericum perforatum, Juglandis semen (Ceviz), Lycium barbarum L. (Gojiberry meyvesi), Mucuna pruriens (Kadife fasülye), Paeoniae Alba Radix (Beyaz Şakayık Kökü), Peganum harmala L., Plumbago scandens, Pueraria lobata, Resveratrol, Thuja orientalis and Vicia faba (Bakla) bulunmaktadır. Daha ileri çalışmalar ile bu doğal kaynaklı bitkilerden yeni ilaçlar hazırlamak mümkün olabilir.

Anahtar Kelimeler: Yaşlı; Parkinson hastalığı; şifalı bitkiler; geleneksel tıp
REFERENCES:
  1. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006;5(6):525-35. [Crossref]  [PubMed] 
  2. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci. 2002;14(2):223-36; discussion 222. [Crossref]  [PubMed] 
  3. Lill CM. Genetics of Parkinson's disease. Mol Cell Probes. 2016;30(6):386-96. Erratum in: Mol Cell Probes. 2020;52:101537. [Crossref]  [PubMed] 
  4. Tysnes OB, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna). 2017;124(8):901-5. [Crossref]  [PubMed] 
  5. Tinelli M, Kanavos P, Grimaccia F. The Value of Early Diagnosis and Treatment in Parkinson's Disease (A Literature Review of the Potential Clinical and Socioeconomic Impact of Targeting Unmet Needs in Parkinson's Disease). 1st ed. England: LSE Consulting; 2016.
  6. Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, Hasan K, et al. Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's disease. Clin Neurosci Res. 2006;6(5):261-81. [Crossref]  [PubMed]  [PMC] 
  7. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114 ( Pt 5):2283-301. [Crossref]  [PubMed] 
  8. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015-22. [Crossref]  [PubMed] 
  9. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-858. Erratum in: Lancet. 2019;393(10190):e44. [PubMed]  [PMC] 
  10. Rogers G, Davies D, Pink J, Cooper P. Parkinson's disease: summary of updated NICE guidance. BMJ. 2017;358:j1951. Erratum in: BMJ. 2019;364:l961. [Crossref]  [PubMed] 
  11. Jenner P. Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future. Transl Neurodegener. 2015;4:3. [Crossref]  [PubMed]  [PMC] 
  12. National Center for Complementary and Integrative Health [Internet]. Complementary, alternative, or integrative health: What's in a name? 2021. (Cited: January 28, 2022). Available from: [Link] 
  13. Finseth TA, Hedeman JL, Brown RP 2nd, Johnson KI, Binder MS, Kluger BM. Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson's disease patients in colorado. Evid Based Complement Alternat Med. 2015;2015:874849. [Crossref]  [PubMed]  [PMC] 
  14. Zheng GQ. Therapeutic history of Parkinson's disease in Chinese medical treatises. J Altern Complement Med. 2009;15(11):1223-30. [Crossref]  [PubMed] 
  15. Yin R, Xue J, Tan Y, Fang C, Hu C, Yang Q, et al. The positive role and mechanism of herbal medicine in Parkinson's disease. Oxid Med Cell Longev. 2021;2021:9923331. [Crossref]  [PubMed]  [PMC] 
  16. Zhang G, Xiong N, Zhang Z, Liu L, Huang J, Yang J, et al. Effectiveness of traditional Chinese medicine as an adjunct therapy for Parkinson's disease: a systematic review and meta-analysis. PLoS One. 2015;10(3):e0118498. [Crossref]  [PubMed]  [PMC] 
  17. Amro MS, Teoh SL, Norzana AG, Srijit D. The potential role of herbal products in the treatment of Parkinson's disease. Clin Ter. 2018;169(1):e23-e33. [PubMed] 
  18. Rajendran PR, Thompson RE, Reich SG. The use of alternative therapies by patients with Parkinson's disease. Neurology. 2001;57(5):790-4. [Crossref]  [PubMed] 
  19. Ovallath S, Deepa P. The history of parkinsonism: descriptions in ancient Indian medical literature. Mov Disord. 2013;28(5):566-8. [Crossref]  [PubMed] 
  20. Fujikawa T, Miguchi S, Kanada N, Nakai N, Ogata M, Suzuki I, et al. Acanthopanax senticosus Harms as a prophylactic for MPTP-induced Parkinson's disease in rats. J Ethnopharmacol. 2005;97(2):375-81. [Crossref]  [PubMed] 
  21. Valverde G De Andrade D, Madureira de Oliveria D, Barreto G, Bertolino LA, Saraceno E, et al. Effects of the extract of Anemopaegma mirandum (Catuaba) on Rotenone-induced apoptosis in human neuroblastomas SH-SY5Y cells. Brain Res. 2008;1198:188-96. [Crossref]  [PubMed] 
  22. Jyoti A, Sharma D. Neuroprotective role of Bacopa monniera extract against aluminium-induced oxidative stress in the hippocampus of rat brain. Neurotoxicology. 2006;27(4):451-7. [Crossref]  [PubMed] 
  23. Chaudhari KS, Tiwari NR, Tiwari RR, Sharma RS. Neurocognitive effect of nootropic drug Brahmi (Bacopa monnieri) in Alzheimer's disease. Ann Neurosci. 2017;24(2):111-22. [Crossref]  [PubMed]  [PMC] 
  24. Zhao T, Tang H, Xie L, Zheng Y, Ma Z, Sun Q, et al. Scutellaria baicalensis Georgi. (Lamiaceae): a review of its traditional uses, botany, phytochemistry, pharmacology and toxicology. J Pharm Pharmacol. 2019;71(9):1353-69. [Crossref]  [PubMed] 
  25. Jeong K, Shin YC, Park S, Park JS, Kim N, Um JY. Ethanol extract of Scutellaria baicalensis Georgi prevents oxidative damage and neuroinflammation and memorial impairments in artificial senescense mice. J Biomed Sci. 2011;18:14. [Crossref]  [PubMed]  [PMC] 
  26. Li XX, He GR, Mu X, Xu B, Tian S, Yu X, et al. Protective effects of baicalein against rotenone-induced neurotoxicity in PC12 cells and isolated rat brain mitochondria. Eur J Pharmacol. 2012;674(2-3):227-33. [Crossref]  [PubMed] 
  27. Mu X, He GR, Yuan X, Li XX, Du GH. Baicalein protects the brain against neuron impairments induced by MPTP in C57BL/6 mice. Pharmacol Biochem Behav. 2011;98(2):286-91. [Crossref]  [PubMed] 
  28. Ding J, Tan X, Song K, Ma W, Xiao J, Song Y, et al. Bushen huoxue recipe alleviates implantation loss in mice by enhancing estrogen-progesterone signals and promoting decidual angiogenesis through FGF2 during early pregnancy. Front Pharmacol. 2018;9:437. [Crossref]  [PubMed]  [PMC] 
  29. Yang MH, Li M, Dou YQ, Liu Y, Luo XD, Chen JZ, et al. [Effects of Bushen Huoxue Granule on motor function in patients with Parkinson's disease: a multicenter, randomized, double-blind and placebo-controlled trial]. Zhong Xi Yi Jie He Xue Bao. 2010;8(3):231-7. Chinese. [Crossref]  [PubMed] 
  30. Li M, Yang MH, Liu Y. [Effects of Chinese herbal medicine Bushen Huoxue Granule on quality of life of patients with Parkinson disease: a randomized, double-blinded and placebo-controlled trial]. Zhong Xi Yi Jie He Xue Bao. 2012;10(3):310-7. Chinese. [Crossref]  [PubMed] 
  31. Ablat N, Lv D, Ren R, Xiaokaiti Y, Ma X, Zhao X, et al. Neuroprotective effects of a standardized flavonoid extract from safflower against a rotenone-induced rat model of Parkinson's disease. Molecules. 2016;21(9):1107. [Crossref]  [PubMed]  [PMC] 
  32. Ju MS, Kim HG, Choi JG, Ryu JH, Hur J, Kim YJ, et al. Cassiae semen, a seed of Cassia obtusifolia, has neuroprotective effects in Parkinson's disease models. Food Chem Toxicol. 2010;48(8-9):2037-44. [Crossref]  [PubMed] 
  33. Frawley D, Ranade S. Ayurveda, Nature's Medicine. 2nd ed. Wisconsin: Lotus Press; 2012.
  34. Haleagrahara N, Ponnusamy K. Neuroprotective effect of Centella asiatica extract (CAE) on experimentally induced parkinsonism in aged Sprague-Dawley rats. J Toxicol Sci. 2010;35(1):41-7. [Crossref]  [PubMed] 
  35. Orhan IE. Centella asiatica (L.) urban: from traditional medicine to modern medicine with neuroprotective potential. Evid Based Complement Alternat Med. 2012;2012:946259. [Crossref]  [PubMed]  [PMC] 
  36. Sun B, Wu L, Wu Y, Zhang C, Qin L, Hayashi M, et al. Therapeutic potential of Centella asiatica and its triterpenes: a review. Front Pharmacol. 2020;11:568032. [Crossref]  [PubMed]  [PMC] 
  37. Kim IS, Koppula S, Park PJ, Kim EH, Kim CG, Choi WS, et al. Chrysanthemum morifolium Ramat (CM) extract protects human neuroblastoma SH-SY5Y cells against MPP+-induced cytotoxicity. J Ethnopharmacol. 2009;126(3):447-54. [Crossref]  [PubMed] 
  38. Jung WS, Kwon S, Cho SY, Park SU, Moon SK, Park JM, et al. The effects of chunghyul-dan (A Korean medicine herbal complex) on cardiovascular and cerebrovascular diseases: a narrative review. Evid Based Complement Alternat Med. 2016;2016:2601740. [Crossref]  [PubMed]  [PMC] 
  39. Ko CN, Park IS, Park SU, Jung WS, Moon SK, Park JM, et al. Neuroprotective effect of Chunghyuldan (Qing Xue Dan) on hypoxia-reoxygenation induced damage of neuroblastoma 2a cell lines. Chin J Integr Med. 2013;19(12):940-4. [Crossref]  [PubMed] 
  40. Tung BT, Nham DT, Hai NT, Thu DK. Curcuma longa, the polyphenolic Curcumin compound and pharmacological effects on liver. In: Watson R, Preedy VR, eds. Dietary Interventions in Liver Disease Foods, Nutrients, and Dietary Supplements. 1st ed. London, United Kingdom: Academic Press; 2019. p.125-34. [Crossref] 
  41. Labban L. Medicinal and pharmacological properties of Turmeric (Curcuma longa): A review. J Pharm Biomed Sci. 2014;5(1):17-23. [Link] 
  42. Gupta SC, Patchva S, Koh W, Aggarwal BB. Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol. 2012;39(3):283-99. [Crossref]  [PubMed]  [PMC] 
  43. Silva AH, Fonseca FN, Pimenta AT, Lima MS, Silveira ER, Viana GS, et al. Pharmacognostical analysis and protective effect of standardized extract and rizonic acid from erythrina velutina against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. Pharmacogn Mag. 2016;12(48):307-12. [PubMed]  [PMC] 
  44. Jang JH, Son Y, Kang SS, Bae CS, Kim JC, Kim SH, et al. Neuropharmacological potential of gastrodia elata blume and its components. Evid Based Complement Alternat Med. 2015;2015:309261. [Crossref]  [PubMed]  [PMC] 
  45. Liu Y, Gao J, Peng M, Meng H, Ma H, Cai P, et al. A review on central nervous system effects of gastrodin. Front Pharmacol. 2018;9:24. [Crossref]  [PubMed]  [PMC] 
  46. Kim IS, Choi DK, Jung HJ. Neuroprotective effects of vanillyl alcohol in Gastrodia elata Blume through suppression of oxidative stress and anti-apoptotic activity in toxin-induced dopaminergic MN9D cells. Molecules. 2011;16(7):5349-61. [Crossref]  [PubMed]  [PMC] 
  47. Zhang J, Sun HM, Bai LM, Xu H, Wu HX, Cui L. [Effect of Ginkgo biloba Pingchan Recipe on neuronal nitric oxide synthase mRNA expression in the brain of mouse models of Parkinson disease]. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29(8):1735-40. [PubMed] 
  48. Ahmad M, Saleem S, Ahmad AS, Yousuf S, Ansari MA, Khan MB, et al. Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences. J Neurochem. 2005;93(1):94-104. [Crossref]  [PubMed] 
  49. Oztürk Y, Aydin S, Beis R, Başer KH, Berberoglu H. Effects of Hypericum perforatum L. and Hypericum calycinum L. extracts on the central nervous system in mice. Phytomedicine. 1996;3(2):139-46. [Crossref]  [PubMed] 
  50. Mohanasundari M, Srinivasan MS, Sethupathy S, Sabesan M. Enhanced neuroprotective effect by combination of bromocriptine and Hypericum perforatum extract against MPTP-induced neurotoxicity in mice. J Neurol Sci. 2006;249(2):140-4. [Crossref]  [PubMed] 
  51. Sánchez-Reus MI, Gómez del Rio MA, Iglesias I, Elorza M, Slowing K, Benedí J. Standardized Hypericum perforatum reduces oxidative stress and increases gene expression of antioxidant enzymes on rotenone-exposed rats. Neuropharmacology. 2007;52(2):606-16. [Crossref]  [PubMed] 
  52. Oliveira AI, Pinho C, Sarmento B, Dias AC. Neuroprotective activity of hypericum perforatum and its major components. Front Plant Sci. 2016;7:1004. [Crossref]  [PubMed]  [PMC] 
  53. Choi JG, Park G, Kim HG, Oh DS, Kim H, Oh MS. In vitro and in vivo neuroprotective effects of walnut (juglandis semen) in models of Parkinson's disease. Int J Mol Sci. 2016;17(1):108. [Crossref]  [PubMed]  [PMC] 
  54. Zhang Z, Liu X, Wu T, Liu J, Zhang X, Yang X, et al. Selective suppression of cervical cancer Hela cells by 2-O-β-D-glucopyranosyl-L-ascorbic acid isolated from the fruit of Lycium barbarum L. Cell Biol Toxicol. 2011;27(2):107-21. [Crossref]  [PubMed] 
  55. Pearson JN, Patel M. The role of oxidative stress in organophosphate and nerve agent toxicity. Ann N Y Acad Sci. 2016;1378(1):17-24. [Crossref]  [PubMed]  [PMC] 
  56. Cao S, Du J, Hei Q. Lycium barbarum polysaccharide protects against neurotoxicity via the Nrf2-HO-1 pathway. Exp Ther Med. 2017;14(5):4919-27. [Crossref]  [PubMed]  [PMC] 
  57. Katzenschlager R, Evans A, Manson A, Patsalos PN, Ratnaraj N, Watt H, et al. Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. J Neurol Neurosurg Psychiatry. 2004;75(12):1672-7. [Crossref]  [PubMed]  [PMC] 
  58. Pulikkalpura H, Kurup R, Mathew PJ, Baby S. Levodopa in Mucuna pruriens and its degradation. Sci Rep. 2015;5:11078. [Crossref]  [PubMed]  [PMC] 
  59. Manyam BV, Dhanasekaran M, Hare TA. Neuroprotective effects of the antiparkinson drug Mucuna pruriens. Phytother Res. 2004;18(9):706-12. [Crossref]  [PubMed] 
  60. Lampariello LR, Cortelazzo A, Guerranti R, Sticozzi C, Valacchi G. The magic velvet bean of mucuna pruriens. J Tradit Complement Med. 2012;2(4):331-9. [Crossref]  [PubMed]  [PMC] 
  61. Rakel D. Parkinson's disease. Integrative Medicine. 4th ed. Philadelpia: Elsevier; 2018. p.143-51.
  62. Liu DZ, Xie KQ, Ji XQ, Ye Y, Jiang CL, Zhu XZ. Neuroprotective effect of paeoniflorin on cerebral ischemic rat by activating adenosine A1 receptor in a manner different from its classical agonists. Br J Pharmacol. 2005;146(4):604-11. [Crossref]  [PubMed]  [PMC] 
  63. Liu DZ, Zhu J, Jin DZ, Zhang LM, Ji XQ, Ye Y, et al. Behavioral recovery following sub-chronic paeoniflorin administration in the striatal 6-OHDA lesion rodent model of Parkinson's disease. J Ethnopharmacol. 2007;112(2):327-32. [Crossref]  [PubMed] 
  64. Lopez-Real A, Rey P, Soto-Otero R, Mendez-Alvarez E, Labandeira-Garcia JL. Angiotensin-converting enzyme inhibition reduces oxidative stress and protects dopaminergic neurons in a 6-hydroxydopamine rat model of Parkinsonism. J Neurosci Res. 2005;81(6):865-73. [Crossref]  [PubMed] 
  65. Rezaei M, Nasri S, Roughani M, Niknami Z, Ziai SA. Peganum Harmala L. Extract Reduces Oxidative Stress and Improves Symptoms in 6-Hydroxydopamine-Induced Parkinson's Disease in Rats. Iran J Pharm Res. 2016;15(1):275-81. [PubMed]  [PMC] 
  66. Morais LC, Quintans-Júnior LJ, Franco CI, Almeida JR, Almeida RN. Antiparkinsonian-like effects of Plumbago scandens on tremorine-induced tremors methodology. Pharmacol Biochem Behav. 2004;79(4):745-9. [Crossref]  [PubMed] 
  67. Zhou YX, Zhang H, Peng C. Puerarin: a review of pharmacological effects. Phytother Res. 2014;28(7):961-75. [Crossref]  [PubMed] 
  68. Xiao B, Sun Z, Cao F, Wang L, Liao Y, Liu X, et al. Brain pharmacokinetics and the pharmacological effects on striatal neurotransmitter levels of Pueraria lobata isoflavonoids in rat. Front Pharmacol. 2017;8:599. [Crossref]  [PubMed]  [PMC] 
  69. Zhang X, Xiong J, Liu S, Wang L, Huang J, Liu L, et al. Puerarin protects dopaminergic neurons in Parkinson's disease models. Neuroscience. 2014;280:88-98. [Crossref]  [PubMed] 
  70. Frémont L. Biological effects of resveratrol. Life Sci. 2000;66(8):663-73. [Crossref]  [PubMed] 
  71. Bhat KPL, Kosmeder JW 2nd, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal. 2001;3(6):1041-64. [Crossref]  [PubMed] 
  72. Lu KT, Ko MC, Chen BY, Huang JC, Hsieh CW, Lee MC, et al. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. J Agric Food Chem. 2008;56(16):6910-3. [Crossref]  [PubMed] 
  73. Ju MS, Lee P, Kim HG, Lee KY, Hur J, Cho SH, et al. Protective effects of standardized Thuja orientalis leaves against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. Toxicol In Vitro. 2010;24(3):759-65. [Crossref]  [PubMed] 
  74. Kempster PA, Bogetic Z, Secombei JW, Martin HD, Balazs ND, Wahlqvist ML. Motor effects of broad beans (Vicia faba) in Parkinson's disease: single dose studies. Asia Pac J Clin Nutr. 1993;2(2):85-9. [PubMed] 
  75. Rijntjes M. Knowing your beans in Parkinson's disease: a critical assessment of current knowledge about different beans and their compounds in the treatment of Parkinson's disease and in animal models. Parkinsons Dis. 2019;2019:1349509. [Crossref]  [PubMed]  [PMC] 

.: Up To Date

.: Process List

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com